Welcoming Remarks. Ehrin J. Armstrong, MD, MSc, MAS, FSCAI
How Do We Identify Patients With Polyvascular Disease, and What Are the Outcomes of Polyvascular Disease? Ehrin J. Armstrong, MD, MSc, MAS, FSCAI
Antithrombotic Agents for Patients With Polyvascular Disease: Before and After Peripheral Vascular Intervention. Marc P. Bonaca, MD, MPH
What Is the Role of SGLT2 and PCSK9 Inhibitors for Patients With Polyvascular Disease? William Schuyler Jones, MD
Treatment of Carotid, Coronary, and Peripheral Artery Disease in a Single Patient: How to Manage? Herbert D. Aronow, MD, MPH, FSCAI
Panel Discussion with S. Elissa Altin, MD, FSCAI

This activity is supported by Janssen. This activity is not certified for Accredited Continuing Education. 

At the end of this activity, participants should be able to:

• Describe the prevalence of atherosclerotic disease in more than one vascular bed and the associated cardiovascular outcomes for these patients.
• Identify best practices for medical therapy of patients with polyvascular disease.
• Create individualized therapeutic strategies to meet the unique challenges of treating polyvascular disease in patients after revascularization.

© 2021-2022 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.